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Upon activation by antigen, B cells form germinal centres where they clon-
ally expand and introduce affinity-enhancing mutations into their B-cell
receptor genes. Somatic mutagenesis and class switch recombination (CSR)
in germinal centre B cells are initiated by the activation-induced cytidine
deaminase (AID). Upon germinal centre exit, B cells differentiate into anti-
body-secreting plasma cells. Germinal centre maintenance and terminal fate
choice require transcriptional reprogramming that associates with a sub-
stantial reconfiguration of DNA methylation patterns. Here we examine
the role of ten-eleven-translocation (TET) proteins, enzymes that facilitate
DNA demethylation and promote a permissive chromatin state by oxidiz-
ing 5-methylcytosine, in antibody-mediated immunity. Using a conditional
gene ablation strategy, we show that TET2 and TET3 guide the transition
of germinal centre B cells to antibody-secreting plasma cells. Optimal AID
expression requires TET function, and TET2 and TET3 double-deficient
germinal centre B cells show defects in CSR. However, TET2/TET3 dou-
ble-deficiency does not prevent the generation and selection of high-affinity
germinal centre B cells. Rather, combined TET2 and TET3 loss-of-function
in germinal centre B cells favours C-to-T and G-to-A transition mutagene-
sis, a finding that may be of significance for understanding the aetiology of
B-cell lymphomas evolving in conditions of reduced TET function.
Introduction
Epigenetic regulation at the level of DNA is largely
mediated by covalent addition of a methyl moiety at
the 5th carbon of cytosines via DNA methyltrans-
ferases (DNMT) [1]. 5-methylcytosine (5mC), enriched
in the context of CpG dinucleotides, associates with a
local repression of gene expression [2]. Embryonic
development is accompanied by a vast turnover of
DNA methylation, guiding developmental transitions
and ultimately stabilizing cell identity. It has been
assumed that the DNA methylation patterns that are
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established during embryonic development are self-per-
petuating and not substantially altered in adult tissues.
Yet, mounting evidence suggests that context-depen-
dent changes in DNA methylation may be functional
during postnatal lineage priming, commitment and cell
function [3–8].
Ten-eleven-translocation (TET) proteins (TET1,
TET2 and TET3) catalyse the iterative oxidation of
the 5mC methyl moiety to 5-hydroxymethylcytosine
(5hmC), 5-formylcytosine and 5-carboxylcytosine [9–
12], with 5hmC being 10- to 100-fold more prevalent
than its higher oxidized states [13]. 5hmC is enriched
in the gene bodies of highly transcribed genes and at
active enhancers [14,15], and 5hmC accumulation in
the latter positively correlates with chromatin accessi-
bility. Despite representing persistent epigenetic marks
on their own, oxidized cytosine species are also func-
tional intermediates for TET-mediated DNA demethy-
lation. Yet the underlying molecular mechanisms are
poorly understood. Oxidized cytosines may facilitate
replication-dependent passive dilution of methylated
cytosines, or mark 5mC for active replacement by
unmodified cytosines through deamination and glyco-
sylase-dependent excision and repair [10,12,16–18].
In vivo, TET-deficiency associates with the deregula-
tion of embryonic development [19], and TET2 loss-
of-function poses a risk for transformation such as in
myeloid malignancies [20–22] or Diffuse Large B-cell
Lymphoma (DLBCL) [23,24], the latter tumour origi-
nating from germinal centre (GC) B cells.
Germinal centres are transient structures in sec-
ondary lymphoid tissues that are initiated by B cells
upon engagement of their cell surface B-cell antigen
receptor (BCR) by antigen, such as during pathogen
infection or vaccination [25,26]. During the GC reac-
tion, the enzyme activation-induced cytidine deaminase
(AID) is vital for the induction of somatic hypermuta-
tion (SHM) and class-switch recombination (CSR) at
the BCR gene loci. Clonally expanding GC B cells suc-
cessively reprogramme their transcriptome, eventually
differentiating into memory B cells or antibody-secret-
ing cells, that is plasma cells that produce large
amounts of high-affinity antibodies.
The transcriptional signatures that separate B-cell
progenitors from mature na€ıve B cells, and mature
na€ıve B cells from functionally distinct progeny are
established by ordered and stepwise reconfiguration of
the DNA methylome [27–31]. In humans, an estimated
30% of the entire DNA methylome is modified during
B-cell development, affecting several million CpG sites
[30,32]. B-cell-specific deletion of DNMT1 in mice
resulted in a complete block in early B-cell develop-
ment [33]. Using conditional mouse models, we and
others have demonstrated that a combined lack of
TET2 and TET3 from early B-cell development on
prevents focal DNA hypomethylation at enhancers
that are enriched for consensus binding motifs of key
B-lineage transcription factors, and consequently cor-
rupts the gene expression programme associated with
maturation transitions [34,35]. The transcription fac-
tors PU.1 and EBF1 were shown to interact with and
possibly recruit TET2 to target regulatory elements
[35,36], suggesting a sequence-specific mechanism of
TET-mediated DNA demethylation. Double-deficiency
of TET2 and TET3 partially blocked pro-B to pre-B-
cell transition, impaired BCR light chain rearrange-
ment and resulted in reduced numbers of peripheral
mature B cells. Of note, these mature B cells were non-
responsive to T-cell-dependent immunization [34].
Preventing DNA methylation has been shown to ter-
minate GCs [33]. In contrast, much remains to be
learned about the role of TET enzymes in the GC
response and for humoral immunity. To this aim, we
generated a mouse model of acute joint ablation of
TET2 and TET3 in established GC B cells, and report
a vital role for TET function in antibody-mediated
immunity.
Results and Discussion
TET2 and TET3 are expressed throughout B-cell
development and terminal differentiation
Human and mouse B cells express TET2 and TET3,
whereas TET1 is barely detectable throughout devel-
opment and upon activation [37–40]. To analyse the
relative mRNA expression of TET2 and TET3 in cell
populations spanning the entire B-cell lineage, we
FACS-sorted developing and mature na€ıve B-cell sub-
sets from unchallenged wild-type mice and antigen-ex-
perienced B cells from mice that were immunized with
sheep red blood cells (RBC), and performed quantita-
tive real-time PCR (qRT-PCR).
During B-cell development expression of both, TET2
(Fig. 1A) and TET3 (Fig. 1B) is progressively increas-
ing, peaking in splenic transitional 1 B cells. Such a
pattern indicates that the two proteins may have par-
tially overlapping functions in developmental transi-
tions or the selection of immature B cells, potentially
controlling the appearance of autoimmune or nonfunc-
tional mature B cells. However, a robust understanding
of TET-function in peripheral immature and mature
na€ıve B-cell subsets could only be achieved using condi-
tional Cre transgenes with selective activity in the cell
type of interest. As compared to mature na€ıve follicular
(FO) B cells, TET2 and TET3 are substantially down-
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regulated in antigen-experienced GC B cells and
plasma cells, a result in agreement with a recent report
in human GC B cells [37] (compare Fig. 1A and B; FO
vs. GC vs. PC). GC B cells cyclically migrate between
the GC dark zone (DZ), where they undergo clonal
expansion and SHM, and the GC light zone (LZ)
where cells expressing a high-affinity BCR are posi-
tively selected. Whereas TET3 mRNA is not differen-
tially expressed between the DZ centroblasts (CB) and
the LZ centrocytes (CC), TET2 reaches its lowest level
in centrocytes. Altogether, these results indicate that
TET2 and TET3 might serve both, overlapping and
unique functions in antibody-mediated immunity.
Dependent on the mouse strain and animal facility,
young mice lacking only TET2 or TET3 display no or
only moderate B-cell phenotypes at steady state
[34,41,42]. Hence, we reasoned that only combined
deletion of TET2 and TET3 may unravel significant
TET-dependent effects in B cells upon activation.
Combined loss of TET2 and TET3 impairs
plasmablast differentiation in vitro
B-cell transit through the GC is accompanied by
extensive DNA demethylation, focal methylation gains
and an overall increased heterogeneity in DNA methy-
lation patterns [30,31,43]. DNMT1 hypomorphic mice
present with a diminished GC size and abundance
upon challenge [28]. This suggests that maintenance of
a specific DNA methylation pattern during the GC
reaction is critical. Enforced DNA demethylation upon
in vitro treatment of activated B cells with 5-azacy-
tidine augmented the appearance of plasmablasts in a
division-dependent manner [31]. Conversely, inhibition
of DNA demethylation might impair plasma cell gen-
eration.
Addressing the involvement of TET proteins in this
process, we generated Cg1-Cre;Tet2F/F;Tet3F/F mice in
which physiologic germ-line Cg1 transcription drives
expression of the Cre-recombinase [44]. Using this sys-
tem, joint Cre-mediated deletion of both Tet genes is
expected in a majority of GC B cells upon IgG1-prim-
ing. Of note, acute GC B cell-specific Tet deletion cir-
cumvents indirect effects caused by extended TET-
deficiency during B-cell development.
First, we used a co-culture system that allows the
generation and exponential growth of in vitro induced
GC (iGC) B cells [45]. In this system, mature na€ıve B
cells are cultured on feeder cells that stably express
CD40 ligand and secrete BAFF thus mimicking T cell
help. Dependent on the cytokine provided, that is
exclusive exposure to IL-4 for 8 days or initial expo-
sure for 4 days to IL-4 followed by IL-21 for another
4 days, this culture allowed us to determine the depen-
dency of iGC B cells on TET-proteins for prolifera-
tion, CSR and plasmablast generation.
After 4 days of iGC culture, acute Tet deletion is
complete as indicated by qRT-PCR analysis (Fig. 2A).
A B
Fig. 1. mRNA expression of TET2 and TET3 in B cells ex vivo. B-cell populations were FACS-sorted from bone marrow and spleens of 8-
wk-young wild type mice (Development and Mature; n = 3) or spleens from 9-wk-young wild type mice that has been immunized with
sheep RBC 7 days before (Antigen activated; n = 3), and RNA was isolated for qRT-PCR analysis for (A) TET2 and (B) TET3 expression.
HPRT was used as reference gene. Bone marrow: pro B cells, large and small pre B cells and immature IgM+ B cells. Spleen: transitional 1
(T1) B cells, transitional 2 (T2) B cells, mature follicular (FO) B cells, marginal zone (MZ) B cells, germinal centre (GC) B cells and
plasmablasts/plasma cells (PC). GC B cells were further divided into dark zone centroblasts (CB) and light zone centrocytes (CC). Data are
shown as mean  SD.
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Within the limited duration of the 8 days culture sys-
tem, double-deficiency of TET2 and TET3 did not
alter cell growth, as indicated by an identical increase
in cellularity between control and Cg1-Cre;Tet2F/F;
Tet3F/F iGC B cell cultures (Fig. 2B). This is consistent
with a comparable fraction of apoptotic cells
(Fig. 2C). To confirm in an independent culture sys-
tem that TET-deficiency does not impact the prolifera-
tion of activated B cells, na€ıve B cells were labelled
with a proliferation-tracking dye and stimulated with
aCD40/IL-4/IL-21 or LPS/IL-4/IL-5. No alterations in
proliferation between the genotypes were observed
(Fig. 2D) despite the highly efficient and division-inde-
pendent deletion of Tet2 and Tet3 after 3 days in cul-
ture (Fig. 2E). In TET-proficient B cells, both TET
mRNAs were down-regulated in a cell division cycle-
dependent manner, albeit with different kinetics.
Whereas TET2 was initially down-regulated and mod-
erately up-regulated in division cycles 5–6, down-regu-
lation of TET3 was only apparent once the cells had
divided > 4 times. From these results a picture emerges
where GC B cells down-regulate TET proteins to pre-
vent premature terminal differentiation, and up-regula-
tion of TET2 is required for optimal plasmablast
differentiation. This is in line with Dominguez et al.
[46] who propose that low TET2 levels, such as in
patients with clonal hematopoiesis of indeterminate
potential that present with TET2 loss-of-function
mutations [47], prevent terminal differentiation hence
facilitating B lymphomagenesis.
The cytokine milieu in the iGC culture system
favours CSR from IgM to IgG1 or IgE. CSR to these
two isotypes was significantly though moderately
impaired in Cg1-Cre;Tet2F/F;Tet3F/F cells (Fig. 2F).
Strikingly, IL-21-driven differentiation into CD138+
plasmablasts, antibody-secreting precursors of long-
lived plasma cells, was strongly diminished (Fig. 2G).
Accordingly, the amount of IgG1 and IgE secreted
into the medium was significantly reduced in TET2/
TET3 double-deficient iGC B cell cultures (Fig. 2H).
The dependence of B cells on TET activity for CSR to
IgG1 and plasmablast differentiation could be recapit-
ulated using an independent culture system (Fig. 2I,J).
Hence, our data suggest that TET function is essential
for proper plasmacytic differentiation. TET2 might
serve a dominant role, as it was shown to cause the
demethylation of intronic CpGs in the Prdm1 locus
encoding BLIMP-1 [46], a key transcriptional repressor
for plasmacytic differentiation.
We note that we have not yet assessed a causal rela-
tionship between TET activity and the methylation
changes during plasmacytic differentiation. While the
distribution of 5hmC has been determined in various
B-cell subsets [30,31], technical limitations prevent so
far a direct identification of the genomic regions where
TET2 and TET3 exert their functions.
Targeted hypomethylation at cis-regulatory sites
might be initiated by the binding of transcription fac-
tors such as EBF1 [35], that subsequently recruit TET
proteins allowing for 5hmC deposition. Focally
demethylated regions were found enriched for binding
motifs for NF-jB and AP-1 or IRF4 and Oct-2 tran-
scription factors during early and late phases of plas-
mablast differentiation respectively [31]. However, how
transcription factor-assisted recruitment of TET
enzymes and consequential oxidation of 5mC result in
targeted DNA demethylation is still a matter of
debate. 5hmC-mediated DNA demethylation may
occur in an enzyme-dependent active, or a replication-
coupled passive manner [40]. Given that plasmablast
differentiation is tightly coupled to cell division [43], it
is likely that passive dilution of oxidized cytosine spe-
cies accounts for a substantial fraction of the observed
global demethylation. In accordance, a recent report
has described a progressive replication-dependent loss
of 5hmC in activated B cells in the absence of TET
function [40]. Nevertheless, as TET2/TET3 double-de-
ficiency does not impair cell growth in culture
(Fig. 2B,D) despite preventing plasmacytic differentia-
tion (Fig. 2G,H,J), our results support the idea that
TET function during plasmablast generation does not
depend on proliferation. This is consistent with a
report by Caron et al. [43] concluding that DNA
demethylation during plasmacytic differentiation
in vitro is associated with the deposition of 5hmC at
regions undergoing targeted demethylation, indepen-
dent of proliferation. Next, we turned our attention to
the humoral immune response in vivo.
TET-deficiency restricts IgG1 production in vivo
We assessed the levels of antibodies circulating in the
peripheral blood of TET2/TET3 double-deficient mice
at steady-state. Of note, Cg1-Cre-mediated recombina-
tion mostly involves IgG1, whereas IgM+ B cells largely
retain the loxP-flanked gene [44]. In accordance,
steady-state levels of IgM in peripheral blood were
unchanged in Cg1-Cre;Tet2F/F;Tet3F/F mice (Fig. 3A).
However, TET activity was required for optimal IgG1
titres, as indicated by significantly reduced basal IgG1
levels (Fig. 3B). Of note, neither TET2- nor TET3-defi-
ciency resulted in alterations in steady-state IgG1
levels, indicating compensatory potential during
steady-state humoral immunity (Fig. 3B).
To determine whether GC B cell-specific TET2/
TET3 double-deficiency manifests defects in the
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magnitude of antibody production in vivo, we induced
T-cell-dependent humoral immunity by challenging
Cg1-Cre control and Cg1-Cre;Tet2F/F;Tet3F/F mice
with sheep RBC. GC B cells that form in response to
RBC antigens predominately switch to IgG1. Periph-
eral blood was collected at days 5 and 11 post
A
E
G
I J
H
F
B C D
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immunization, and ELISA was performed to deter-
mine the abundance of serum antibody isotypes.
Whereas IgG1 titers increased upon immunization in
Cg1-Cre mice, Cg1-Cre;Tet2F/F;Tet3F/F mice displayed
only a marginal increase in circulating IgG1 from day
0 to day 11 (Fig. 3B).
These in vivo data mirror the defects in antibody
production observed in vitro (Fig. 2H), and indicate
that complete TET loss-of-function impairs humoral
immunity in a GC B-cell-autonomous manner.
Loss of TET-function impairs GC maintenance
and CSR upon immunization
To explore the role of TET proteins in the GC response,
we used an alum-adsorbed hapten-carrier conjugate, 4-
hydroxy-3-nitrophenylacetyl (NP) conjugated to
chicken gamma globulin (NP-CGG). NP-specific GC B
cells that form in response to alum-adjuvanted immuno-
gens predominately switch to IgG1 [48,49]. Joint Tet2
and Tet3 deletion in Cg1-Cre;Tet2F/F;Tet3F/F GC B cells
was efficient by day 10 post immunization (Fig. 4A).
Fourteen days post immunization, flow cytometry anal-
ysis revealed a substantially decreased overall and NP-
specific GC response in Cg1-Cre;Tet2F/F;Tet3F/F mice,
whereas the number and fraction of na€ıve B cells
remained unaltered (Fig. 4B,C). Of note, within the
fraction of GC B cells NP-specific IgG1+ B cells were
further reduced in Cg1-Cre;Tet2F/F;Tet3F/F mice
(Fig. 4C, bar graph). A reduced number of GC was also
evident when performing immunohistochemistry for
PNA and Ki67 on splenic sections of immunized mice
(Fig. 4D). Despite the differential expression of TET2
between dark and light zone GC B cells (Fig. 1A), com-
partmentalization was not phenotypically altered in
Cc1-cre;Tet2F/F;Tet3F/F mice (Fig. 4E). Within the total
GC B-cell population we observed a striking deficit for
CSR from IgM to IgG1 (Fig. 4F), in accordance with
the impaired CSR observed in vitro (Fig. 2F). Overall,
these results indicate that TET proteins positively con-
trol the magnitude of the GC reaction, and facilitate
CSR to IgG1.
Ki67 mRNA levels are unaltered in FACS-sorted
Cg1-Cre;Tet2F/F;Tet3F/F GC B cells, suggesting that
these cells proliferate normally (Fig. 2G). A recent
report showed that the bZIP transcription factor BATF
recruits TET proteins to TET-responsive regulatory ele-
ments in the AID gene locus, promoting 5hmC deposi-
tion and demethylation, sustaining chromatin
accessibility and bolstering AID expression [50]. Consis-
tent with this report and the observed CSR defect in
Cg1-Cre;Tet2F/F;Tet3F/F GC B cells, AID mRNA levels
were found decreased by 50% in GC B cells (Fig. 4G)
[50]. Despite the fact that optimal AID expression is
required for efficient CSR [50], transcriptional regula-
tion of AID may not be the only mechanism by which
TET proteins mediate AID function. Recently, AID-
mediated recruitment of TET2 to the FANCA locus and
associated demethylation has been described in human
lymphoma cell lines [39]. Hence, it appears possible that
AID recruits TET enzymes to further gene loci during
somatic hypermutation. We wondered whether the
reduced AID levels would impair affinity maturation in
Cg1-Cre;Tet2F/F;Tet3F/F GC B cells.
Cg1-Cre;Tet2F/F;Tet3F/F mice show compromised
serum a-NP IgG1 levels
Following immunization with NP-CGG, we deter-
mined the abundance and affinity of serum
Fig. 2. Combined loss of TET2 and TET3 impairs plasmablast differentiation in vitro. (A) qRT-PCR analysis for TET2 and TET3 mRNA
expression in iGC B cells cultivated in vitro for 4 days (n = 3 for each genotype). (B) Population doublings of iGC B cells cultured on 40LB
feeder cells with IL-4 for 4 days, and additional 4 days with either IL-4 or IL-21. Numbers of live cells were determined via Trypan blue
exclusion (n = 4/genotype). (C) Intracellular flow cytometry analysis for active (cleaved) caspase 3 performed on iGC B cells cultivated
in vitro for 8 days (n = 3/genotype/condition). (D) Splenic na€ıve B cells were labelled with a proliferation-tracking dye (Cell Proliferation Dye
eF450) and stimulated with aCD40/IL-4/IL-21 or LPS/IL-4/IL-5 for 72 h. Loss of the tracking dye was assessed by flow cytometry. Numbers
above individual peaks represent the respective division-cycles. Overlay histograms are representative of three mice per genotype. (E) qRT-
PCR analysis for TET2 and TET3 on aCD40/IL-4/IL-21-stimulated FACS-sorted B cells that had divided for a defined number of times (n = 3
for each genotype); cells were derived from the cultures described in (D) and for each biological replicate divisions 1–2, 3–4 and 5–6 were
pooled into one sample. (F) Representative flow cytometry plots (left; day 8 with IL-21) and bar graphs (right) depicting IgM+ or switched
(IgG1+ and IgE+ combined) cells within total iGC B cells (n = 6 for Cg1-Cre and n = 4 for Cg1-Cre;Tet2F/F;Tet3F/F). Of note, the fraction of B
cells neither IgM+, IgE+ nor IgG1+ (approximately 20% per sample) was not further investigated. (G) Representative flow cytometry plots
(left; day 8 with IL-21) and bar graphs (right) depicting the fraction of CD138hi plasmablasts within total iGC B cells (n = 8 for Cg1-Cre and
n = 8 for Cg1-Cre;Tet2F/F;Tet3F/F). (H) Bar graphs depicting ELISA results for antibodies secreted into the culture medium (n = 3 for Cg1-Cre
and n = 3 for Cg1-Cre;Tet2F/F;Tet3F/F). (I) Flow cytometry plots depicting switched IgG1+ B cells upon stimulation with LPS/IL-4/IL-5 for
3 days. Plots are representative of three mice per genotype. (J) Flow cytometry plots depicting CD138+ plasmablasts upon stimulation with
LPS/IL-4/IL-5 for 3 days. Plots are representative of three mice per genotype. Data are shown as mean  SD. *P < 0.05, **P < 0.01,
***P < 0.005, ****P < 0.0001 vs Cg1-Cre control (unpaired Student’s t-test).
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antibodies specific to NP by ELISA. Cg1-Cre;Tet2F/
F;Tet3F/F mice produced nearly similar amounts of
NP-specific IgM antibodies compared with Cg1-Cre
control mice at 14 days post immunization (Fig. 5A).
In contrast, immunized Cg1-Cre;Tet2F/F;Tet3F/F mice
had substantially less circulating NP-specific IgG1 in
the peripheral blood as compared to Cg1-Cre control
mice (Fig. 5B). Despite a two-fold reduction in NP-
specific IgG1, the levels of both total (NP18-BSA)
and high-affinity (NP1.7-BSA) a-NP IgG1 were
decreased similarly, resulting in no significant skew-
ing of the affinity ratio in Cg1-Cre;Tet2F/F;Tet3F/F
mice (Fig. 5B).
Within the limits of this experimental approach, our
results indicate that TET activity compromises a-NP
IgG1 quantity but not quality. The lack of phenotype
in affinity maturation appeared surprising given the
reduced levels of AID in Cg1-Cre;Tet2F/F;Tet3F/F GC
B cells (Fig. 4G), and motivated us to explore SHM in
more detail.
Loss of TET function does not impair affinity
maturation but alters the mutation spectrum
Antibody affinity increases throughout affinity matura-
tion, ultimately leading to the generation of highly pro-
tective neutralizing antibodies. The NP-CGG model is
amenable to SHM analysis as humoral immune
responses against carrier-coupled NP are dominated by
B cells carrying the VH186.2 gene rearrangement
[51,52]. We FACS-sorted B220+CD19+CD138
CD95hiCD38lo/IgG1+ cells from the spleens of three
Cg1-Cre control and three Cg1-Cre;Tet2F/F;Tet3F/F
mice 14 days post immunization. After RNA isolation,
a region of 315 nucleotides of the VH186.2-constant
region g1 gene encompassing CDR1 and CDR2 was
amplified, sequenced and mutations in 30 unique GC
B-cell clones per genotype were analysed by compar-
ison with the germ-line VH186.2 gene sequence.
The well-characterized tryptophan to leucine switch
at position 33 of VH186.2 (W33L) [53], conferring a
10-fold increase in the BCR affinity for NP, was
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Fig. 3. TET-deficiency restricts the levels of circulating IgG1 in vivo. ELISA for IgM (A) and IgG1 (B) was performed on sera from
unchallenged (steady state; n = 16 for Cg1-Cre, n = 4 for Tet2F/F;Tet3F/F, n = 8 for Cg1-Cre;Tet2F/F, n = 6 for Cg1-Cre; Tet3F/F and n = 15
for Cg1-Cre;Tet2F/F;Tet3F/F mice) and sheep RBC-immunized mice (days 5 and 11; n = 3 for Cg1-Cre and n = 3 for Cg1-Cre;Tet2F/F;Tet3F/F).
Data are shown as mean  SD. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001 vs Cg1-Cre;Tet2F/F;Tet3F/F mice (One-way ANOVA
and Tukey post-hoc test for multiple comparisons; unpaired Student’s t-test when comparing two groups).
Fig. 4. Loss of TET-function impairs GC maintenance and CSR upon immunization. (A) qRT-PCR analysis for TET2 and TET3 mRNA
expression in FACS-sorted splenic GC B cells of the indicated genotypes 5 and 10 days post immunization with NP-CGG (n = 3 for Cg1-Cre
and n = 3 for Cg1-Cre;Tet2F/F;Tet3F/F). (B) Mice of the indicated genotypes were immunized at the age of 8–10 weeks with NP-CGG and
analysed 14 days later. Flow cytometry analysis of splenic single-cell suspensions identified the fractions of total B cells (B220+CD19+), GC
B cells (CD19+B220+CD138CD95hiCD38lo/) and NP+IgG1+ GC B cells within total splenocytes. Total cell numbers for the respective cell
populations are shown (n = 5 for Cg1-Cre and n = 5 for Cg1-Cre;Tet2F/F;Tet3F/F). (C) Representative flow cytometry plots (left) and bar
graph (right; n = 5 for Cg1-Cre and n = 5 for Cg1-Cre;Tet2F/F;Tet3F/F) depict fractions of B cells, GC B cells and IgG1+NP+ GC B cells shown
in (B). Arrows indicate gating strategy. (D) Spleen sections from the indicated genotypes 14 days post immunization with NP-CGG were
analysed for Ki67 (proliferating cells) and for the ability of cells to bind PNA (GC B cells). The brown precipitate indicates positive staining.
Sections were counterstained with haematoxylin. One representative mouse out of three per group is shown. Scale bars: 200 lm. (E)
Representative flow cytometry plots (left) depict fractions of DZ and LZ GC B cells within total GC B cells. Scatter graph (right; n = 5 for
Cg1-Cre and n = 5 for Cg1-Cre;Tet2F/F;Tet3F/F) shows the ratio of DZ and LZ GC B cells. (F) Scatter graph depicts the ratio of IgM+ and
IgG1+ cells within GC B cells (n = 5 for Cg1-Cre and n = 5 for Cg1-Cre;Tet2F/F;Tet3F/F). (G) qRT-PCR analysis for Ki67 and AID mRNA in
FACS-sorted na€ıve Cg1-cre B cells (n = 3) and GC splenic B cells (n = 3 for Cg1-Cre and n = 3 for Cg1-Cre;Tet2F/F;Tet3F/F) 14 days post NP-
CGG immunization. Data are shown as mean  SD. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001 vs Cg1-Cre control (Student’s t-
test).
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comparably frequent in Cg1-Cre control (55%) and
Cg1-Cre;Tet2F/F;Tet3F/F (54%) GC B-cell clones
(Fig. 6A). These data are in accordance with the
ELISA results in Fig. 5. Furthermore, NP-specific GC
B cells from Cg1-Cre;Tet2F/F;Tet3F/F mice exhibited
similar fractions of amino acid replacement and silent
mutations across the entire length of VH186.2
(Fig. 6B). Hence, SHM appears phenotypically unal-
tered in GC B cells deficient for TET2 and TET3.
Our current analysis is limited to the hapten NP, a
simple antigen where a few specific mutations suffice for
efficient affinity maturation. It will be interesting in the
future to test the impact of TET activity on the forma-
tion of broadly neutralizing antibodies upon infection
with pathogens carrying complex antigens, such as HIV
or influenza that are characterized by extraordinary fre-
quencies of affinity-enhancing mutations.
Methylated CpG dinucleotides are a mutation hot-
spot in human cancers, a phenomenon that has been
linked to the propensity of 5mC to deaminate.
Hydroxymethylation of cytosines has been reported
to enhance [54] or reduce [55] the likelihood of muta-
tions. Hence, the modification state of cytosine likely
influences the mutability of DNA, however, the rela-
tionship between mutability and cytosine modifica-
tions remains poorly understood. We found that Cg1-
Cre;Tet2F/F;Tet3F/F GC B cells carried slightly less
somatic mutations per VH186.2 sequence (Fig. 6C),
though this difference did not reach statistical signifi-
cance. Strikingly, however, VH186.2 mutations in
TET-deficient GC B cells exhibited C-to-T and G-to-
A transition mutation biases (Fig. 6D). In GC B
cells, mutagenesis is largely a consequence of AID
activity [56]. In accordance with our results, B-cell-
specific Tet2-deficiency promoted age-dependent trans-
formation in a fraction of mice, an outcome that
strictly required AID and involved a bias towards G-
to-A and C-to-T mutations in the established
tumours [38]. This suggests that TET proteins may at
least partially exert their tumour suppressor activity
in GC B cell-derived lymphomas by orchestrating the
mutagenic potential of AID. One possible scenario is
that cytidine deaminases (AID and APOBEC1-3)
have substantially lower activity on 5hmC compared
to 5mC [57,58]. In addition, deamination of 5mC
produces thymine, whereas 5hmC deaminates to 5-hy-
droxymethyluracil, an atypical base that might be
repaired more efficiently [55]. Alternatively, 5hmC
generated by TET enzymes may promote chromo-
some stability by supporting DNA damage repair
[59]. Up to 10% of human DLBCL exhibit TET2
loss-of-function mutations, and these mutations usu-
ally occur mutually exclusive with mutations in regu-
lators of TET function [46,60]. Finally, reduced TET
function may actively impact on the aetiology of GC
B-cell-derived tumours by shaping the mutational
landscape or increasing chromosomal aberrations.
Concluding remarks
The major goal of this study was to explore whether
TET activity affects the magnitude or quality of humoral
immune responses. Our data emphasize an essential role
of TET function in GC expansion, plasmacytic differen-
tiation and antibody production. The observed relative
reduction in CSR correlated with decreased AID levels.
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Fig. 5. Cg1-Cre;Tet2F/F;Tet3F/F mice show
compromised serum a-NP IgG1 levels. (A)
Serum total (a-NP18-BSA) and high-affinity
(a-NP1.7-BSA) a-NP antibody titres of the (A)
IgM and (B) IgG1 isotypes before (steady
state; n = 4 for Cg1-Cre and n = 4 for Cg1-
Cre;Tet2F/F;Tet3F/F) or 14 days after (day 14;
n = 7 for Cg1-Cre and n = 6 for Cg1-Cre;
Tet2F/F;Tet3F/F) immunization with NP-CGG.
The maturation index is defined as the ratio
of the a-NP18 and a-NP1.7 antibody titres.
Data are shown as mean  SD. *P < 0.05,
**P < 0.01, ***P < 0.005 vs Cg1-Cre
control (Student’s t-test).
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In our model system, affinity maturation did not depend
on TET function and was not limited by reduced AID
levels. Strikingly, however, TET proteins appear to influ-
ence the mutagenic potential of AID as TET deficient
GC B cells showed mutational skewing towards transi-
tion mutations, a function that may be of relevance for
the aetiology of GC B-cell-derived lymphomas and
potentially further tumour entities.
Materials and methods
Mice and immunization
The Cg1-Cre [44], Tet2F [61] and Tet3F [42] alleles have
been described. Male and female littermate mice were used
indiscriminately in this study. Eight- to ten-week-old mice
were immunized i.p. with 100 lg NP-CGG/mouse in a vol-
ume of 200 lL per mouse. Alternatively, mice were injected
i.p. with 1 9 109 sheep RBCs (Labor Dr. Merck, Ochsen-
hausen, Germany, E-400) in PBS in a volume of 200 lL
per mouse. Animal procedures were approved by the Aus-
trian Federal Ministry of Education, Science and Research
(BMWF: 66-011/0106-WF/3b/2015 and 66-011/0031-V/3b/
2019).
Preparation of alum-precipitated NP-CGG
A freshly prepared 10% Alum solution [KAl(SO4)2 (Sigma,
Saint Louis, MO, USA, 31242) in PBS] was mixed with a
similar volume of 1 mgmL1 NP15-CGG (Biosearch Tech-
nologies, Hoddeston, UK, N-5055B-5; prepared in PBS),
A
C D
B
Fig. 6. Loss of TET function does not prevent affinity maturation but alters the mutation spectrum. (A) IgG1+ GC B cells were FACS-sorted
from three Cg1-Cre and three Cg1-Cre;Tet2F/F;Tet3F/F mice 14 days post immunization with NP-CGG, and 10 unique VH186.2 c1 transcripts
per mouse were sequenced. Bar graph depicts the frequency of the W33L affinity-enhancing mutation within the pool of unique GC B-cell
clones for each genotype. (B) Pie charts depict the % of VH186.2 mutations that are silent, lead to an amino acid replacement or a STOP
codon. (C) Column scatter graph depicts the number of mutations in unique VH186.2 BCR sequences for each genotype. Data were
analysed with Mann–Whitney with mean displayed. (D) Bar graph depicts the frequency of total and individual nucleotide transitions or
transversions within the total number of mutations pooled for each genotype. n = 30 correct sequences for Cg1-Cre and n = 28 correct
sequences for Cg1-Cre;Tet2F/F;Tet3F/F.
3575The FEBS Journal 286 (2019) 3566–3581 ª 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
K. Schoeler et al. TET2 and TET3 control humoral immunity
and the pH was adjusted to 6.5–7.0 using 10 M NaOH (pH
indicator; Macherey-Nagel, D€uren, Germany, 92118). The
precipitate was washed three times with PBS at 2348 g for
15 s and finally resuspended in PBS to reach the initial vol-
ume of the Alum/NP-CGG mixture.
Preparation of primary single-cell suspensions
and cell counting
Staining buffer [PBS/3% FBS (Gibco, Grand Island, NY,
USA, 10270-106)] was generally used for cell preparation.
Single-cell suspensions were prepared by forcing murine
spleen through 70 lM mesh filters (Corning, Cambridge,
MA, USA, 352350), or flushing both femurs and tibiae
using a 23G needle. Erythrocytes were depleted by incubat-
ing cells for 3 min in 1 mL lysis buffer (155 mM NH4Cl,
10 mM KHCO3, 0.1 mM EDTA; pH7.5) on ice. Cells were
washed with staining buffer and filtered through a 50 lM
cup filcon (BD Biosciences, San Diego, CA, USA, 340632),
and cell numbers were determined using a hemocytometer
and trypan blue exclusion.
iGC B cell culture
B cells were enriched from splenic single-cell suspensions
using MagniSort Streptavidin Negative Selection Beads
(Thermo Fisher Scientific, Waltham, MA, USA, MSNB-
6002-74) as per manufacturer’s instructions, and biotiny-
lated antibodies against Ter119 (BioLegend, San Diego,
CA, USA, 116204, 1 : 100), CD11b (BioLegend, 101204,
1 : 100) and TCRb (BioLegend, 109204, 1 : 50).
The iGC B cell culture was conducted as described by
Nojima et al. [45]. Briefly, 40LB feeder cells were expanded
in feeder cell medium: DMEM (Sigma, WHMISDZB) sup-
plemented with 10% FBS (Gibco, 10270-106), 2 mM L-glu-
tamine (Sigma, G7513) and 100 UmL1 penicillin/
100 lgmL1 streptomycin (Sigma, 0781). 3 9 106 feeder
cells per 10 cm plate were treated for 2 h with 10 lgmL1
mitomycin C (Sigma, M0305) in 6 mL feeder cell medium.
Following five repeated washing steps with PBS, 1.5 9 106
B cells/10 cm dish were plated on 40LB feeder cells in
40 mL B-cell medium: DMEM supplemented with 10% (v/
v) FBS, 2 mM L-glutamine, 10 mM Hepes (LONZA, Basel,
Switzerland, BE17-737E), 1 mM sodium pyruvate (Gibco,
13360-039), 19 nonessential amino acids (Gibco, 11140-
035), 100 UmL1 penicillin/100 lgmL1 streptomycin,
50 lM b-mercapto-ethanol (Sigma, M3148) and 10 ngmL1
rIL-4 (Peprotech, Rocky Hill, NJ, USA, 214-14). On day 3,
30 mL of medium containing IL-4 were replaced. On day
4, iGC B cells were harvested and analysed. 1.5 9 106 iGC
B cells were replated per 10 cm dish containing fresh mito-
mycin C-treated 40LB feeder cells as detailed above, and
cultivated in 40 mL of B-cell medium containing either
10 ngmL1 rIL-4 or 10 ngmL1 rIL-21 (Peprotech, 210-
21). Thirty millilitre of medium containing the respective
cytokines were replaced by fresh medium on day 7. The
final analysis was conducted on day 8. Analyses (day 4 and
8) entailed collection of medium for ELISA and pellets for
qRT-PCR, cell counting (Trypan blue exclusion) and flow
cytometric analysis. For analysis, iGC B cells were gener-
ally handled at room temperature and cultured at 37 °C in
a humidified atmosphere containing 5% CO2.
In vitro stimulation of B cells
Primary B cells were enriched from splenic single-cell sus-
pensions and cultivated in medium as described above for
the iGC B-cell culture at 37 °C in a humidified atmosphere
containing 5% CO2. Mitogenic stimuli were used as fol-
lows: 1 lgmL1 a-CD40 (Thermo Fisher Scientific, 16-
0402-85), 25 ngmL1 IL-4 (Peprotech, 214-14),
10 ngmL1 IL-21 (Peprotech 210-21), 20 mgmL1
lipopolysaccharide (Sigma, L2880) and 25 ngmL1 IL-5
(Peprotech, 215-15).
To determine cell proliferation in the presence of mito-
gens in vitro, B cells were labelled with 10 lM Cell Prolifer-
ation Dye eFluor 450 (Thermo Fisher Scientific, 65-0842-
90) as per manufacturer’s instructions and placed in cul-
ture.
Flow cytometry analysis of ex vivo isolated cells
Flow cytometry analysis has been performed as described
in Ref. [62] using the following fluorochrome-labelled anti-
bodies: aB220-PerCP/Cy5.5 (BioLegend, 103236, 1 : 300),
aB220-BV510 (BioLegend, 103247, 1 : 300), aCD19-BV605
(BioLegend, 115540, 1 : 300), aCD19-BV421 (BioLegend,
115538, 1 : 300), aAA4.1-PE/Cy7 (BioLegend, 136507,
1 : 400), aAA4.1-APC (BioLegend, 136510 1 : 400), aIgM
F(ab0)2-FITC (Jackson ImmunoResearch, 115-096-072,
1 : 300), aCD25-PE (BioLegend, 102007, 1 : 400), acKit-
APC (BioLegend, 135108, 1 : 300), aCD1d-PE (Thermo
Fisher Scientific, 12-0011-82, 1 : 500), aCD23-PE/Cy7 (Bio-
Legend, 101614, 1 : 400), aCD38-FITC (BioLegend,
102705, 1 : 300), aCD38-APC (BioLegend, 102712,
1 : 400), aCD38-eFluor450 (Thermo Fisher Scientific, 48-
0381-80, 1 : 300), aCD95-PE (BD Biosciences, 554258,
1 : 300), aCD95-PE/Cy7 (BD Biosciences, 557653, 1 : 800),
aCXCR4-APC (BioLegend, 146508, 1 : 100), aCD86-PE/
Cy7 (BioLegend, 105014, 1 : 100), aIgG1-FITC (BD Bio-
sciences, 553443, 1 : 200), aIgG1-PE (BD Biosciences,
550083, 1 : 200), CD138-PE (BioLegend, 142504, 1 : 300)
and CD138-BV510 (BioLegend, 142521, 1 : 200). NP24-PE
(Biosearch Technologies, N-5070-1, 1 : 500) was used to
detect NP-binding B cells. Data were acquired on an LSRII
cytometer (BD Biosciences) and analysed using FLOWJO
software (Tree Star, Ashland, OR, USA). Nonsinglet events
were excluded from analyses using FSC-H/FSC-W and
SSC-H/SSC-W characteristics.
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Flow cytometry analysis of iGC B cells
To collect iGC B cells from 10 cm dishes, 9/10 of the med-
ium was gently removed, and the cells were incubated for
5 min at 37 °C in 3 mL harvest buffer (PBS/0.5% BSA/
2 mM EDTA). Cells were harvested by addition of B-cell
medium and vigorous pipetting.
For CSR analysis, 5 9 105 iGC B cells were washed
twice with 1 mL PBS at room temperature and 460 g for
4 min. Subsequently, the cells were resuspended in 250 lL
of 37 °C 0.05% trypsin (Sigma, T4174) and surface
digested for 4 min at 37 °C. To stop trypsin digestion,
3 mL of staining buffer (described above for flow cytome-
try) were added, the cells were pelleted at 1800 r.p.m. for
4 min and the supernatant was removed. The cells were
transferred to a U-bottom 96 well plate and dead cells were
labelled with the Fixable Viability Dye eFluor 780 (Thermo
Fisher Scientific, 65-0865-14) as per manufacturer’s instruc-
tions. Subsequently, cells were fixed and processed using
the active Caspase 3 staining kit (BD Biosciences, 550914)
as per manufacturer’s instructions. Before staining with the
active Caspase 3 antibody, the iGC B cells were incubated
with 1 lgmL1 of aCD16/32 Fc-Block (BioLegend,
101310) in 25 lL perm/wash buffer for 10 min at 4 °C.
Subsequently another 25 lL of aIgE-bio (BD Biosciences,
553419, 1 : 400) diluted in perm/wash buffer was added,
the cells were further incubated for 15 min at 4 °C and
washed with perm/wash buffer at 568 g for 2 min. Next,
the cells were incubated with 25 lL of antibody mix con-
taining aIgM-PeCy7 (Thermo Fisher Scientific, 25-5790-81,
1 : 500), aIgG1-FITC (BD Biosciences, 562026, 1 : 300),
aCD19-BV605 (BioLegend, 115540, 1 : 300) and Strepta-
vidin-APC (BioLegend, 405207, 1 : 800) for 15 min at
4 °C. The cells were washed with perm/wash buffer at
2000 r.p.m. for 2 min and stained for active caspase 3 as
per manufacturer’s instructions.
The processing of cells for plasmablast flow cytometry
analysis was performed at room temperature in the dark.
5 9 105 iGC B cells were transferred to a U-bottom 96
well plate and pelleted at 2000 r.p.m. for 2 min. Dead cells
were labelled with the Fixable Viability Dye eFluor 780
(Thermo Fisher Scientific, 65-0865-14) as per manufac-
turer’s instructions. Subsequently, cells were incubated
with 1 lgmL1 of aCD16/32 Fc-Block in 25 lL staining
buffer (PBS/3%FBS) for 10 min. Next, 25 lL of staining
buffer containing aCD19-BV605 (BioLegend, 115540,
1 : 300) and aCD138-BV421 (BioLegend, 142508, 1 : 300)
was added. The cells were further incubated for 15 min,
washed with 200 lL of staining buffer at 2000 r.p.m. for
2 min, and resuspended in 200 lL staining buffer for flow
cytometry analysis.
Data were acquired on an LSRII cytometer (BD Bio-
sciences) and analysed using FLOWJO software (Tree Star).
Nonsinglet events were excluded from analyses using FSC-
H/FSC-W and SSC-H/SSC-W characteristics.
Cell sorting
Cell sorting has been performed as described in Ref. [62].
Briefly, bone marrow or splenic single-cell suspensions were
pre-incubated with 1 lgmL1 of aCD16/32 Fc-Block in
500 lL staining buffer (PBS/3%FBS) for 10 min, washed
and stained for 20 min with antibodies in a volume of
500 lL staining buffer. The sorted cell subsets were defined
as follows: Bone Marrow: pro B cells (B220loC-
D19+AA4.1+IgMCD25ckit+), large pre B cells (B220loC-
D19+AA4.1+IgMCD25+ckitFSChi), small pre B cells
(B220loCD19+AA4.1+IgMCD25+ckitFSClo) and imma-
ture IgM+ B cells (B220loCD19+AA4.1+IgM+). Spleen: T1 B
cells (CD19+B220+AA4.1+CD23IgMhi), T2 B cells (CD19+
B220+AA4.1+CD23+IgMhi), FO B cells (CD19+B220+AA
4.1CD1d+IgM+), MZ B cells (CD19+B220+AA4.1CD1-
dhiIgMhi), GC B cells (CD19+B220+CD138CD95hiCD38lo/),
plasma cells/plasmablasts (B220/loCD138hi), DZ GC B cells
(CD19+B220+CD138CD95hiCD38lo/CXCR4hiCD86lo) and
LZ GC B cells (CD19+B220+CD138CD95hiCD38lo/
CXCR4loCD86hi). For sorting B-cell division cycles cells were
harvested, filtered through 70 lM mesh filters (Corning,
352350) and resuspended in staining buffer.
Cell sorting was carried out on a FACS Aria III (BD
Biosciences). Nonsinglet events were excluded from analy-
ses based on characteristics of FSC-H/FSC-W and SSC-H/
SSC-W.
Quantitative real-time-PCR
RNA from snap-frozen cell pellets of FACS-sorted B cells
was isolated using the Quick-RNA Micro Prep Kit (Zymo
Research, Irvine, CA, USA, R1050) and DNase digestion
as per manufacturer’s instructions. RNA from snap-frozen
in vitro-cultivated B cells was isolated using Trizol reagent
(Thermo Fisher Scientific, 15596026) as per manufacturer’s
instructions. DNA was removed using the RQ1 RNAse-
free DNase (Promega, Madison, WI, USA, M610A), and
RNA was retrieved using GlycoBlue Coprecipitant
(Thermo Fisher Scientific, AM9515) as per manufacturer’s
instructions. First-strand cDNA was generated from 100 ng
of total RNA using the iScript cDNA Synthesis Kit (Bio-
Rad, Hercules, CA, USA, 170-8891) and cDNA was ampli-
fied using the AceQ qPCR SYBR Green Master Mix
(Vazyme biotech, Nanjing, China, Q111-02) as per manu-
facturer’s instructions. The qRT-PCR was run on a StepO-
nePlus Real-time PCR system (Applied Biosystems, Foster
City, CA, USA) and melt curve analysis was performed for
every run. The expression of individual mRNAs was nor-
malized to HPRT with the following formula: fold induc-
tion = 2ðDCtÞ, where DCt ¼ CtðtargetÞ  CtðHPRTÞ . The following
primers were used: HPRT F: 50-GTCATGCCGACCCGC
AGTC-30, HPRT R: 50-AGTCCATGAGGAATAAAC-30;
TET2 F: 50-GCCAGAAGCAAGAAACCAAG-30, TET2
R: 50-TTGGAGCAATGACAGTAGCC-30; TET3 F: 50-A
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AGAGTCTGCTGGACACACC-30, TET3 R: 50-CTCCAT-
GAGTTCCCGGATAG-30; AID F: 50-GGACTTCGGCCA
CCTTC-30, AID R: 50-CATCTCAGAAACTCAGCCACG-
30. Ki67 F: 50-GAACAGACTTGCTCTGGCCTAC-30,
Ki67 R: 50- CTTCATAGGCATTCCCTCACTC-30.
ELISA
For NP-specific serum IgG1 and IgM titres, ELISA was
performed as described in [62]. For total immunoglobulin
levels in serum or secreted immunoglobulin in iGC culture
medium, 50 lgmL1 capture antibody (Southern Biotech,
1010-01) was coated overnight onto 96-well enzyme-linked
immunosorbent assay plates at 4 °C (Sigma, CLS3590).
Plates were washed three times with wash buffer (PBS con-
taining 0.05% TWEEN 20), blocked with 100 lL per well
1% BSA in PBS for 4 h at room temperature and washed
three more times with wash buffer. Subsequently, wells
were incubated over night at 4 °C with 100 lL per well of
mouse serum serially diluted 1 : 4 in blocking buffer (range
1 : 800 to 1 : 160 000). Plates were washed three times with
wash buffer and incubated with 100 lL per well of HRP-
conjugated a-mouse IgG1 (Southern Biotech, 1070-05,
1 : 5000 in 1% BSA in PBS) or HRP-conjugated a-mouse
IgM (Southern Biotech, 1020-05, 1 : 5000 in 1% BSA in
PBS) for 4 h at room temperature. For detection, 100 lL
of ABTS substrate solution per well [200 lL ABTS (Stock:
15 mgmL1 in a.d.), 10 mL citrate-phosphate buffer
(574 mg citric acid monohydrate in 50 mL a.d.) and 10 lL
H2O2] was incubated for 20 min. Absorbance was mea-
sured at 405 nm using a microplate reader (Tecan Sunrise,
M€annedorf, Switzerland).
Immunohistochemistry
IHC was performed on 7 lm sections of murine spleens as
described in Ref. [62]. Imaging was performed on a Zeiss
Axioplan 2 microscope using a 109 objective (Zeiss, Ober-
kochen, Gemany) and the Axiocam 305 colour camera
(Zeiss). Pictures were generally processed with the ZEISS ZEN
BLUE 2.5 LITE software (Zeiss).
VH186.2 SHM analysis
Somatic hypermutation analysis was performed according
to Ref. [63] for three Cg1-Cre and three Cg1-Cre;Tet2F/F;
Tet3F/F mice. Briefly, IgG1+ GC B cells were FACS-sorted
(CD19+B220+CD138FashiCD38lo/IgG1+), pelleted and
total RNA was isolated using the Quick-RNA Micro Prep
Kit (Zymo Research, R1050) including the DNase digestion
step as per manufacturer’s instructions. First-strand cDNA
was generated from 100 ng of total RNA using the Pro-
mega GoScript Reverse transcription system (Promega,
A5000) and a gene-specific primer for the IgG1 locus: Cg1
50-CATGGAGTTAGTTTGGGCAG-30. Subsequently, two
rounds of semi-nested PCRs were performed using the Her-
culase II Fusion DNA polymerase kit (Agilent, Santa
Clara, CA, USA, 600675) as per manufacturer’s instruc-
tions. Following each round of PCR, the gene product was
run on an agarose gel and purified using the peqGold Gel
extraction kit (VWR, Radnor, PA, USA, 732-2777) as per
manufacturer’s instructions. For the first PCR, the follow-
ing primers were used: V186.2 leader 50-AGCTGTAT-
CATGCTCTTCTTGGCA-30, Cg1 50-CATGGAGTTAGT
TTGGGCAG-30. For the second PCR, the following pri-
mers were used: V186.2 nested 50-CATGCTCTTCTTGG-
CAGCAACAG-30, Cg1 50-CATGGAGTTAGTTTGGG
CAG-30. For cloning of VH186.2 segments, the pJet1.2
blunt vector was used and cleaved with EcoRV (New Eng-
land BioLabs, Ipswich, MA, USA, R0195). The purified
PCR products were ligated into the vector using T4 ligase
(Promega, M1794) as per manufacturer’s instructions.
Using a standard transformation protocol, DH5a bacteria
were transformed with the bulk of ligated plasmids, spread
onto LB Agar/ampicillin plates and incubated over night at
37 °C. For each of the six mice, >10 colonies were trans-
ferred into a PCR Master Mix (Vazyme Biotech, P211),
and the very same colonies were selected on new LB agar
plates. For the colony PCR, the following primers were
used: pJet1.2 F 50-CGACTCACTATAGGGAGAGCGGC-
30, pJet1.2 R 50-AAGAACATCGATTTTCCATGGCAG-
30. Cycle conditions were: 1 cycle: 95 °C for 1 min; 30
cycles: 95 °C for 15 s, 56 °C for 15 s, 72 °C for 45 s; 1
cycle: 72 °C for 3 min. The PCR products were loaded
onto an agarose gel, and colonies with correct insertions
were grown in 2 mL LB medium over night. Plasmid DNA
was extracted using the Monarch Plasmid Miniprep Kit
(New England BioLabs, T1010L) as per manufacturer’s
instructions. Subsequently, Sanger sequencing was per-
formed using the pJet1.2 F primer detailed above.
Sequences were aligned to the VH186.2 germ line sequence
using VBASE2 (http://www.vbase2.org/). Mutation data
were only used if the entire sequence was intact, and only
unique sequences were included in the analysis. According
to these criteria, two sequences from Cg1-Cre;Tet2F/F;
Tet3F/F GC B cells had to be excluded.
Quantification and statistical analysis
Results are always shown as mean and standard deviation
(SD). Graphs were plotted and statistical analysis was per-
formed with GRAPHPAD PRISM 7 software (San Diego, CA,
USA) using Student’s t test when comparing two groups,
One-way ANOVA and Tukey post hoc test when comparing
multiple groups and Mann–Whitney test for SHM analysis.
The number of biological repetitions (n) is stated in each fig-
ure legend, and every experiment was performed at least
twice. Differences between groups were considered statisti-
cally significant when P < 0.05. In figures, asterisks stand
for: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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